Réalisées par des traducteurs professionnels, des entreprises, des pages web ou traductions disponibles gratuitement.
trastuzumab se leagă selectiv de un antigen numit factorul de creştere epidermal uman, her2.
trastuzumab binds selectively to an antigen called human epidermal growth factor 2 (her2).
Dernière mise à jour : 2012-04-11
Fréquence d'utilisation : 2
Qualité :
anticorpii monoclonali ai egfr (receptorul factorului de creştere epidermal) în asociere cu schema chimioterapică cu bevacizumab
egfr monoclonal antibodies in combination with bevacizumab chemotherapy regimens
Dernière mise à jour : 2017-04-26
Fréquence d'utilisation : 1
Qualité :
erlotinib „ blochează ” receptorii factorului de creştere epidermal care se găsesc la suprafaţa anumitor celule tumorale.
erlotinib blocks the epidermal growth factor receptors, which can be found on the surface of certain tumour cells.
Dernière mise à jour : 2012-04-11
Fréquence d'utilisation : 2
Qualité :
trastuzumab este conceput pentru a se lega selectiv de un antigen numit receptorul factorului de creştere epidermal uman 2 (her2).
trastuzumab is designed to bind selectively to an antigen called human epidermal growth factor receptor 2 (her2).
Dernière mise à jour : 2017-04-26
Fréquence d'utilisation : 1
Qualité :
trastuzumab a fost creat pentru a se lega de her2, un receptor pentru factorul de creştere epidermal, care se găseşte la suprafaţa anumitor celule canceroase.
her2, a receptor for epidermal growth factor, which is found on the surface of certain tumour cells.
Dernière mise à jour : 2012-04-11
Fréquence d'utilisation : 2
Qualité :
tarceva este un medicament utilizat în tratamentul cancerului, împiedicând activitatea unei proteine numite receptor al factorului de creştere epidermal (egfr).
tarceva is a medicine used to treat cancer by preventing the activity of a protein called epidermal growth factor receptor (egfr).
Dernière mise à jour : 2017-04-26
Fréquence d'utilisation : 1
Qualité :
este utilizat la pacienţii în cazul cărora celulele canceroase prezintă mutaţii ale genelor care produc o proteină numită receptor al factorului de creştere epidermal (egfr).
it is used in patients whose cancer cells have a mutation in the genes that make a protein called epidermal growth factor receptor (egfr).
Dernière mise à jour : 2017-04-26
Fréquence d'utilisation : 1
Qualité :
estimates of the relative cytotoxicity of the middle ultraviolet, near ultraviolet and violet regions of sunlight on epidermal keratinocytes, cancer research 47, p. 1825-1829.
estimates of the relative cytotoxicity of the middle ultraviolet, near ultraviolet and violet regions of sunlight on epidermal keratinocytes, cancer research 47, pp. 1825-1829.
erlotinibul este un inhibitor de tirozin kinază a receptorului factorului de creştere epidermal/a receptorului de tip 1 al factorului de creştere epidermal uman (egfr cunoscut şi sub denumirea de her1).
erlotinib is an epidermal growth factor receptor/human epidermal growth factor receptor type 1 (egfr also known as her1) tyrosine kinase inhibitor.
substanţa activă din tarceva, erlotinib, este un medicament împotriva cancerului din grupa „ inhibitorilor receptorilor factorului de creştere epidermal (egfr) ”.
the active substance in tarceva, erlotinib, is an anti-cancer medicine that belongs to the group ‘ epidermal growth factor receptor (egfr) inhibitors’.
la pacienţii cu psoriazis trataţi cu infliximab s-a obţinut scăderea inflamaţiei epidermale şi normalizarea diferenţierii keratinocitelor la nivelul plăcii psoriazice.
in psoriasis patients, treatment with infliximab resulted in decreases in epidermal inflammation and normalization of keratinocyte differentiation in psoriatic plaques.
